Resleeve gastrectomy (ReSG) is a surgical option for patients experiencing insufficient weight loss or weight regain after primary sleeve gastrectomy (P-SG). However, national-level data on the comparative perioperative safety of ReSG versus P-SG remain limited.

Metabolic and Bariatric surgery (MBS) has become an essential treatment for severe obesity and associated comorbidities, particularly type 2 diabetes mellitus (T2DM), with substantial benefits in weight loss, improved glycemic control, and cardiovascular risk reduction. The International Diabetes Federation (IDF) recognizes MBS as an effective option for individuals with obesity with T2DM due to its ability to improve insulin sensitivity and lower inflammation. These surgeries induce metabolic improvements through distinct mechanisms that affect gut hormone secretion, nutrient absorption, and energy balance. These interventions modulate key gut hormones like glucagon-like peptide-1 (GLP-1), ghrelin, and leptin, which influence appetite, glucose metabolism, and fat storage. Moreover, MBS alters the gut microbiome, contributing to enhanced metabolic function and the resolution of obesity-related conditions. Theories such as the Foregut-Hindgut Hypothesis, Ileal Brake Mechanism, and Gastric Center Hypothesis further try explain these metabolic changes. Understanding these theories and the physiological alterations they provoke is crucial for optimizing patient care and advancing the future of obesity treatments, offering insights into mechanisms that go beyond simple weight loss to address complex metabolic disorders.

Prior research has shown higher rates of complications across a broad spectrum of surgeries in pediatric patients with higher Social Vulnerability Index (SVI).

Health care access is influenced by geographic, socioeconomic, and systemic factors. For patients undergoing metabolic and bariatric surgery (MBS), travel distance may reflect disparities in service availability, insurance limitations, and referral patterns to specialized centers.

Increasing obesity and metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis present challenges in liver transplantation.

The incidence of bariatric surgery in younger adults, and subsequently conversional surgery, is increasing.

While new medications are transforming the management of obesity, their association with outcomes in adolescents undergoing metabolic and bariatric surgery (MBS) is not clear.

There is a need for an instrument that efficiently identifies heart failure (HF) symptoms in patients with obesity.

Obesity is increasingly linked to chronic kidney disease, and most patients with end-stage renal disease would benefit from kidney transplantation. Bariatric surgery is the most effective treatment for obesity and possibly improves postrenal transplant outcomes in patients with obesity.

Obesity increases the risk of metabolic-associated steatotic liver disease (MASLD), and metabolic and bariatric surgery (MBS) mitigates progression to severe and end-stage liver disease (LD). Preoperative LD was added as a new variable for the 2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database, allowing for analysis of this variable on perioperative and postoperative outcomes.

Patients seeking metabolic and bariatric surgery (MBS) are treated by an interdisciplinary team of surgeons and integrated health professionals before and after their surgery. Support groups are required as part of safety and quality of care programs seeking and maintaining accreditation; nevertheless, the research is limited regarding the efficacy and outcomes related to support group attendance. The intention of this systematic review is to summarize current literature surrounding MBS support groups, to identify gaps in the literature, and to provide recommendations for future research regarding support groups, as well as guidance for support group facilitators. Using Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines platform and database searches were conducted for MBS support groups from 1998 to present using PubMed (Medline); Ovid (Medline); APA PsycNet (PsychINFO). Inclusion criteria were English language, adults of any age and adolescents (ages 14-18), and private, hospital, or academic medical center live support groups that follow American Society for Metabolic and Bariatric Surgery standards. Eighteen studies were included in our review. Authors sought to examine the relationship between attendance at facilitator-led, in person or virtual and hybrid support groups and outcomes of weight loss, self-management, and barriers to attendance. Results showed that support group attendance was associated with better weight loss, self-management, and adherence following surgery. This review supports the ongoing need for support group to be part of the interdisciplinary care of patients undergoing MBS. Additional research is needed to address cited gaps in the literature surrounding selection bias, lack of comparison groups, and to determine the impact of hybrid and virtual support groups on patient outcomes.

The rising prevalence of heart failure (HF) and coexisting metabolic syndrome underscores the need to better understand how these conditions affect postoperative outcomes following metabolic and bariatric surgery.